ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug ...

Myocardial Infarction, Cardiovascular Disease, Prevention, Challenges, Review Abdin, A. (2024) Myocardial Infarction and the Prevention Strategies Keeping it at Bay: A Narrative Review. Open Access ...

The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert ...

In this secondary analysis of the MINT trial, 30-day risks for the composite outcome of death and recurrent myocardial ...

A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD.

Early use of mechanical circulatory support did not reduce 6-month all-cause mortality. 2. MCS was associated with increased ...

The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary ...

For patients with acute myocardial infarction (MI) and anemia, 30-day risks for death or recurrent MI seem to increase with ...

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial ...

The following is a summary of “Liberal versus restrictive transfusion strategies in acute myocardial infarction: a systematic review and comparative frequentist and Bayesian meta-analysis of ...

The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose.

A widowmaker heart attack affects the left anterior descending (LAD) artery. Read on to learn the effects and likelihood of ...